Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial

Richard M. Goldberg, Charles Lawrence Loprinzi, James A. Mailliard, Judith R. O'Fallon, James E. Krook, Chirantan Ghosh, Robert D. Hestorff, Sandra Fong Chong, Nicholas F. Reuter, Thomas G. Shanahan

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

Purpose: Based on evidence that suggests pentoxifylline can inhibit tumor necrosis factor, we set out to evaluate the activity and toxicity of this drug in patients with cancer-associated anorexia and/or cachexia. Patients and Methods: Seventy patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 with cancer anorexia and/or cachexia (defined by a weight loss of ≥ 5 lb in the preceding 2 months or a caloric intake < 20 kcal/kg/d) were stratified and then randomly assigned to receive pentoxifylline or identical-appearing placebo tablets in a double-blind fashion. Patients' weights were monitored and patient questionnaires were used to assess appetite, toxicity, and perception of benefit. Results: Pentoxifylline failed to improve the appetites of study patients. Pentoxifylline did not appear to cause any toxicity. Conclusion: This study failed to demonstrate any benefit of pentoxifylline at this dose and schedule as therapy for cancer anorexia and/or cachexia.

Original languageEnglish (US)
Pages (from-to)2856-2859
Number of pages4
JournalJournal of Clinical Oncology
Volume13
Issue number11
StatePublished - Nov 1995

Fingerprint

Pentoxifylline
Cachexia
Anorexia
Placebos
Neoplasms
Appetite
Therapeutics
Energy Intake
Drug-Related Side Effects and Adverse Reactions
Tablets
Weight Loss
Appointments and Schedules
Tumor Necrosis Factor-alpha
Weights and Measures

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Goldberg, R. M., Loprinzi, C. L., Mailliard, J. A., O'Fallon, J. R., Krook, J. E., Ghosh, C., ... Shanahan, T. G. (1995). Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 13(11), 2856-2859.

Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. / Goldberg, Richard M.; Loprinzi, Charles Lawrence; Mailliard, James A.; O'Fallon, Judith R.; Krook, James E.; Ghosh, Chirantan; Hestorff, Robert D.; Chong, Sandra Fong; Reuter, Nicholas F.; Shanahan, Thomas G.

In: Journal of Clinical Oncology, Vol. 13, No. 11, 11.1995, p. 2856-2859.

Research output: Contribution to journalArticle

Goldberg, RM, Loprinzi, CL, Mailliard, JA, O'Fallon, JR, Krook, JE, Ghosh, C, Hestorff, RD, Chong, SF, Reuter, NF & Shanahan, TG 1995, 'Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial', Journal of Clinical Oncology, vol. 13, no. 11, pp. 2856-2859.
Goldberg, Richard M. ; Loprinzi, Charles Lawrence ; Mailliard, James A. ; O'Fallon, Judith R. ; Krook, James E. ; Ghosh, Chirantan ; Hestorff, Robert D. ; Chong, Sandra Fong ; Reuter, Nicholas F. ; Shanahan, Thomas G. / Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. In: Journal of Clinical Oncology. 1995 ; Vol. 13, No. 11. pp. 2856-2859.
@article{0015c27a09d74bc9a28687e97d45abaf,
title = "Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial",
abstract = "Purpose: Based on evidence that suggests pentoxifylline can inhibit tumor necrosis factor, we set out to evaluate the activity and toxicity of this drug in patients with cancer-associated anorexia and/or cachexia. Patients and Methods: Seventy patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 with cancer anorexia and/or cachexia (defined by a weight loss of ≥ 5 lb in the preceding 2 months or a caloric intake < 20 kcal/kg/d) were stratified and then randomly assigned to receive pentoxifylline or identical-appearing placebo tablets in a double-blind fashion. Patients' weights were monitored and patient questionnaires were used to assess appetite, toxicity, and perception of benefit. Results: Pentoxifylline failed to improve the appetites of study patients. Pentoxifylline did not appear to cause any toxicity. Conclusion: This study failed to demonstrate any benefit of pentoxifylline at this dose and schedule as therapy for cancer anorexia and/or cachexia.",
author = "Goldberg, {Richard M.} and Loprinzi, {Charles Lawrence} and Mailliard, {James A.} and O'Fallon, {Judith R.} and Krook, {James E.} and Chirantan Ghosh and Hestorff, {Robert D.} and Chong, {Sandra Fong} and Reuter, {Nicholas F.} and Shanahan, {Thomas G.}",
year = "1995",
month = "11",
language = "English (US)",
volume = "13",
pages = "2856--2859",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial

AU - Goldberg, Richard M.

AU - Loprinzi, Charles Lawrence

AU - Mailliard, James A.

AU - O'Fallon, Judith R.

AU - Krook, James E.

AU - Ghosh, Chirantan

AU - Hestorff, Robert D.

AU - Chong, Sandra Fong

AU - Reuter, Nicholas F.

AU - Shanahan, Thomas G.

PY - 1995/11

Y1 - 1995/11

N2 - Purpose: Based on evidence that suggests pentoxifylline can inhibit tumor necrosis factor, we set out to evaluate the activity and toxicity of this drug in patients with cancer-associated anorexia and/or cachexia. Patients and Methods: Seventy patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 with cancer anorexia and/or cachexia (defined by a weight loss of ≥ 5 lb in the preceding 2 months or a caloric intake < 20 kcal/kg/d) were stratified and then randomly assigned to receive pentoxifylline or identical-appearing placebo tablets in a double-blind fashion. Patients' weights were monitored and patient questionnaires were used to assess appetite, toxicity, and perception of benefit. Results: Pentoxifylline failed to improve the appetites of study patients. Pentoxifylline did not appear to cause any toxicity. Conclusion: This study failed to demonstrate any benefit of pentoxifylline at this dose and schedule as therapy for cancer anorexia and/or cachexia.

AB - Purpose: Based on evidence that suggests pentoxifylline can inhibit tumor necrosis factor, we set out to evaluate the activity and toxicity of this drug in patients with cancer-associated anorexia and/or cachexia. Patients and Methods: Seventy patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 with cancer anorexia and/or cachexia (defined by a weight loss of ≥ 5 lb in the preceding 2 months or a caloric intake < 20 kcal/kg/d) were stratified and then randomly assigned to receive pentoxifylline or identical-appearing placebo tablets in a double-blind fashion. Patients' weights were monitored and patient questionnaires were used to assess appetite, toxicity, and perception of benefit. Results: Pentoxifylline failed to improve the appetites of study patients. Pentoxifylline did not appear to cause any toxicity. Conclusion: This study failed to demonstrate any benefit of pentoxifylline at this dose and schedule as therapy for cancer anorexia and/or cachexia.

UR - http://www.scopus.com/inward/record.url?scp=0028787659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028787659&partnerID=8YFLogxK

M3 - Article

C2 - 7595749

AN - SCOPUS:0028787659

VL - 13

SP - 2856

EP - 2859

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -